Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × Malignant Ascites × Nivolumab × Clear all

Phase

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 3 Skin Neoplasms 2 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Carcinoma 1 Neoplasms 1 Malignant Ascites 1 Lung Neoplasms 1 Glioma 1 Drug-Related Side Effects and Adverse Reactions 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05745233 2023-08-24

Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites

China Medical University Hospital

Phase NA Enrolling by invitation

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon ⚡